New data reveals that retatrutide, a dual-action medication, could represent a significant step in body management. This treatment combines the properties of a GLP-1 receptor and a GIP receptor , seemingly offering a greater outcome than current approaches . Patient assessments have shown promising results , including significant declines in weigh